Karyopharm Announces FDA Approval of XPOVIO® (selinexor) for the Treatment of Patients with Relapsed or Refractory

Награды Comparably

Karyopharm Therapeutics Заявленная компания

Karyopharm is an innovation-driven pharmaceutical company whose core technology leverages the inhibition of nuclear export as a mechanism to treat patients with cancer and other medical conditions читать еще

Эта компания принимает отзывы от проверенных сотрудников СОТРУДНИКИ УЧАСТНИКИ: 90

ИТОГО РЕЙТИНГИ: 2628

СЕО: Richard Paulson

Richard Paulson Karyopharm Therapeutics CEO Rating

Karyopharm Therapeutics' CEO, Richard Paulson, has 52 employee ratings and a score of 82/100, placing them in the Top 5% of similar size companies on Comparably with 201-500 сотрудников and Top 10% of other companies in Boston. When breaking the CEO score down by factors such as department, gender, and ethnicity, we see that females at Karyopharm Therapeutics rate Richard Paulson higher than males, giving the CEO a score of 83/100.

Last updated months ago.

Where This Score Ranks Karyopharm Therapeutics' CEO Rating

TOP
5%
In the Top 5% of 2013 Similar Sized Companies on Comparably
TOP
10%
In the Top 10% of 270 Nearby Companies in Boston
1st
1st place versus 5 competitors rated on Comparably

Nov

Feb

Mar

May

Jun

A+82 / 100

Jan

Karyopharm Therapeutics CEO Richard Paulson Bio

Mr. Paulson was appointed President and Chief Executive Officer of Karyopharm in May 2021 and has served as a member of Karyopharm’s Board of Directors since February 2020. He was previously an Executive Vice President of Ipsen Pharmaceuticals, Inc. and Chief Executive Officer of Ipsen North America, a global biopharmaceutical company focused on innovation and specialty care in areas of oncology, neuroscience and rare diseases, from February 2018 to May 2021. Mr. Paulson previously worked at Amgen for 10 years holding varying leadership positions across Europe and North America, including Vice President and General Manager of Amgen’s U.S. Oncology Business Unit, and prior to that served as the Vice President of Marketing for Amgen’s U.S. Oncology Business, General Manager of Amgen Germany, and General Manager of Amgen Central & Eastern Europe. Prior to Amgen, Mr. Paulson held a number of global leadership positions at Pfizer Inc., including serving as General Manager of Pfizer South Africa and Pfizer Czech Republic. Mr. Paulson also previously held a variety of sales, marketing, and market access roles with increasing seniority at GlaxoWellcome in Canada.

Mr. Paulson has an MBA from the University of Toronto, Canada and an undergraduate degree in commerce from the University of Saskatchewan, Canada.

Who Ranks Karyopharm Therapeutics' CEO Rating the Highest?

Department - IT 90/100

Experience - Entry Level 90/100

Department - Sales 84/100

Who Ranks Karyopharm Therapeutics' CEO Rating the Lowest?

Department - Finance 74/100

Ethnicity - Asian or Pacific Islander 76/100

Department - Legal 77/100

Karyopharm Therapeutics CEO Richard Paulson At a Glance

The CEO score provides an understanding of how employees feel about the CEO’s leadership style and effectiveness at Karyopharm Therapeutics.

Based on 52 ratings, Richard Paulson ranks right above Takeda's CEO, Christophe Weber.

Karyopharm Therapeutics' CEO is highly regarded by the IT department, employees with Entry Level experience, and the Sales department. However, the Finance department, Asian or Pacific Islander employees, and the Legal department have a less favorable view of the CEO and believe there is room for improvement. Overall, the CEO score has remained stable over the last 90 days.